Part of why doctors remain wary of cannabis medicine is the lack of randomized, double-blind, placebo controlled trials — the gold standard for medical research. Because of cannabis’ status as an illicit drug, research is often relegated to retrospective surveys, which are useful but more likely to be biased. But there are methods in between these two schemes, such as open-label trials.
How often have we heard, “More research is needed,” from those who would prefer to see no change in policies that should be informed by science? From climate denial to cannabis prohibition, the demand for absolute scientific certainty is a call for inaction.
It begs the question: When is there “enough” research?
“David,” a 10 year old boy, had his first seizure at 2 months of age. The convulsions were photosensitive generalized tonic-clonic seizures that occurred 1-4 times each day. These events were occurring daily, even though he was being treated with two anti-seizure medications – lamotrigine (Lamictal) and valproic acid. But they had already tried carbamazepine, phenobarbital, zonisamide and levetiracetam (Keppra) without success.
During the last week of June, more than 400 scientists from 25 countries met in Montreal for the 27th annual symposium of the International Cannabinoid Research Society (ICRS). Several presentations and posters showcased new findings about
THCA (tetrahydrocannabinolic acid) is the non-psychoactive acid form of THC found in the plant when raw. THCA converts to THC when it is decarboxylated. Discover the clinical and laboratory research on THCA for epilepsy, chronic pain, digestive disorders, and more.
A cutting edge paper from three cannabis friendly medical professionals—Dustin Sulak, Russel Saneto, and Bonni Goldstein—outlines case reports and the applications of cannabis medicine for epilepsy and seizure disorders.
Low-dose and high-dose treatments, protocols for chronic users, and the potential benefits of psychoactivity.